Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P080 - Efficacy and Safety of Docetaxel Plus Ramucirumab: A Consecutive Analysis of 68 Patients with Advanced NSCLC (ID 214)
00:00 - 00:00 | Author(s): S. Yokota
Docetaxel plus ramucirumab (DTX+RAM) prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. We assessed the efficacy and safety, especially the incidence of febrile neutropenia (FN), in patients who received DTX+RAM.
Consecutive patients who received DTX+RAM between August 2016 and May 2018 were reviewed retrospectively.
A total 68 patients received DTX+RAM. The patients